These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15778428)

  • 41. A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study.
    Salinger DH; Endres CJ; Martin DA; Gibbs MA
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):276-83. PubMed ID: 27128833
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efalizumab, a reversible T-cell modulator for psoriasis.
    Shear NH; Langley RG; Ho V
    J Cutan Med Surg; 2006; 9 Suppl 1():4-9. PubMed ID: 16633862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comment on "Development of monoclonal gammopathy in 12 patients receiving efalizumab treatment for chronic plaque psoriasis".
    Ginarte M
    J Am Acad Dermatol; 2011 Jun; 64(6):1184; author reply 1184-5. PubMed ID: 21571182
    [No Abstract]   [Full Text] [Related]  

  • 46. Efalizumab in the treatment of discoid lupus erythematosus.
    Usmani N; Goodfield M
    Arch Dermatol; 2007 Jul; 143(7):873-7. PubMed ID: 17638731
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis.
    Viguier M; Richette P; Aubin F; Beylot-Barry M; Lahfa M; Bedane C; Delesalle F; Richard-Lallemand MA; Delaporte E; Dubertret L; Bardin T; Bachelez H
    Arthritis Rheum; 2008 Jun; 58(6):1796-802. PubMed ID: 18512820
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A; Gordon KB; Leonardi CL; Gu Y; Goldblum OM
    J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity.
    Xu ZH; Lee H; Vu T; Hu C; Yan H; Baker D; Hsu B; Pendley C; Wagner C; Davis HM; Zhou H
    Int J Clin Pharmacol Ther; 2010 Sep; 48(9):596-607. PubMed ID: 20860913
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exacerbation of pityriasis rubra pilaris under efalizumab therapy.
    Klein A; Szeimies RM; Landthaler M; Karrer S
    Dermatology; 2007; 215(1):72-5. PubMed ID: 17587845
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience.
    Costanzo A; Peris K; Talamonti M; Di Cesare A; Fargnoli MC; Botti E; Chimenti S
    Br J Dermatol; 2007 Apr; 156 Suppl 2():17-23. PubMed ID: 17371319
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.
    Lebwohl M; Yeilding N; Szapary P; Wang Y; Li S; Zhu Y; Reich K; Langley RG; Papp KA
    J Am Acad Dermatol; 2010 Oct; 63(4):571-9. PubMed ID: 20599293
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efalizumab for the treatment of moderate to severe plaque psoriasis.
    Jordan JK
    Ann Pharmacother; 2005 Sep; 39(9):1476-82. PubMed ID: 15998666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series.
    Lowes MA; Turton JA; Krueger JG; Barnetson RS
    BMC Dermatol; 2005 Aug; 5():9. PubMed ID: 16109173
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study.
    Tsai TF; Liu MT; Liao YH; Licu D
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):345-52. PubMed ID: 18005021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis.
    Papp KA; Ho V; Langley R; Lynde C; Poulin Y; Shear N; Toole J; Zip C
    J Cutan Med Surg; 2006; 9 Suppl 1():26-32. PubMed ID: 16633859
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation.
    Vincenti F; Mendez R; Pescovitz M; Rajagopalan PR; Wilkinson AH; Butt K; Laskow D; Slakey DP; Lorber MI; Garg JP; Garovoy M
    Am J Transplant; 2007 Jul; 7(7):1770-7. PubMed ID: 17564637
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients.
    Pang Y; Khatri A; Suleiman AA; Othman AA
    Clin Pharmacokinet; 2020 Mar; 59(3):311-326. PubMed ID: 31758502
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment.
    Bonnekoh B; Pommer AJ; Böckelmann R; Hofmeister H; Philipsen L; Gollnick H
    Skin Pharmacol Physiol; 2007; 20(5):237-52. PubMed ID: 17587888
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New-onset, debilitating arthritis in psoriasis patients receiving efalizumab.
    Myers WA; Najarian D; Gottlieb AB
    J Dermatolog Treat; 2006; 17(6):353-4. PubMed ID: 17853308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.